主页 > 医学动态 >
【原创】阿立哌唑有望成为年销售额逾10亿美元的
依赖阿立哌唑（aripiprazole , Abilify）在美国市道的畅通无阻（该品自2002年FDA批准用于治疗精神分裂症以来，已在美国开出180万张处方），截止3月31日，日本大冢制药株式会社（Otsuka）2004财年药品销售额（包括诊断剂和静脉溶液）上升13.8%达2530亿日元（23亿美元），超过了公司总销售额（4888亿日元，＋3.1%）的一半，其中国外销售额暴涨28.1%达1239亿日元，约占总销售额的四分之一。
该品已于今年3月在其第一个亚洲国家南韩上市。欧盟则已在最近批准该品治疗精神分裂症的上市申请。
大冢认为，鉴于阿立哌唑气候初成，用不了几年，其在美国药市的地位必将扶摇直上，成为年销售额逾10亿美元的巨型炸弹式产品。
然而，大冢在日本国内的形势不容乐观。
虽受保护的抗溃疡药瑞巴匹特(rebamipide，Mucosta)借助颗粒剂新处方，销售额增长4.7% 达 ¥295亿日元，抗凝血药西洛他唑（cilostazol，Pletaal）也因去年批准用于脑梗塞后遗症的附加新适应症销售额增长4.1% 达 ¥229亿日元，但抗哮喘药丙卡特罗（procaterol，Meptin）因新处方拖累销售额下降7.9% 仅 73 亿日元。
并且，由于研究与开发（R&D）费用激增29.7%（419亿日元），大冢同期总营业利润出现了19.7%（110亿日元）的负增长，净利润更是狂跌 45% ，仅为166亿日元。
S00848864 - Scrip Top
Date published: 29 June 2004
Abilify lifts Otsuka's full-year pharma sales
Otsuka Pharmaceutical's consolidated sales of pharmaceuticals (including diagnostics and iv solutions) rose by a robust 13.8% to ¥253 billion ($2.3 billion) in the year ended March 31st, helped by US growth for the schizophrenia product, Abilify (aripiprazole).
The sector accounted for just over half of the private group's total consolidated sales, which rose by 3.1% to ¥488.8 billion. Overall operating profit was 19.7% lower at ¥11 billion, however, while net profit dropped by 45% to ¥16.6 billion, hit in part by a 29.7% increase in non-consolidated R&D spending (to ¥41.9 billion). Helped by Abilify, total overseas sales jumped by 28.1% to ¥123.9 billion, accounting for around a quarter of the total.
Domestic sales of the protective anti-ulcer, Mucosta (rebamipide), were aided by a new granule formulation, rising by 4.7% to ¥29.5 billion. Sales of the platelet anti-aggregant, Pletaal (cilostazol), also grew, by 4.1% to ¥22.9 billion, due in part to the approval last year for the additional indication of sequelae of cerebral infarction. Despite several new formulations, sales of the anti-asthmatic, Meptin (procaterol), fell by 7.9% to ¥7.3 billion.
The company expects Abilify to become a $1 billion product in the US over the next few years (Scrip No 2947, p 12) and it will be launched in its first European markets shortly. South Korea became the first Asian market in March and approval is awaited in Japan. Also awaiting domestic approval is a Clickhaler presentation of Meptin, while a new ophthalmic formulation of Mikelan (carteolol) for glaucoma should be submitted shortly.
Full title: SCRIP - World Pharmaceutical News
FILED 29 June 2004 COPYRIGHT 2004 PJB Publications Ltd [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-29 17:14
医学,生命科学网